An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...

Findings support model in which accelerated biological aging of mammary epithelia may underpin breast cancer susceptibility ...

The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023.  The ...

A recent study published in Cell Reports Medicine has identified distinct microbial signatures within the oral cavity and gut ...

MethylScan is a low-cost blood test that detects multiple cancers and liver diseases by analyzing DNA methylation patterns for affordable early detection.

Researchers at City of Hope, a cancer research and treatment organization, and the University of California, Berkeley, have created a novel microfluidic platform that can assess women's breast cancer ...

Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...

Brazilian researchers have developed an electrochemical sensor that can detect pancreatic cancer in its early stages. The ...

TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...

MethylScan is a low-cost blood test that detects cancers and organ diseases by analyzing DNA methylation, improving early diagnosis, and identifying disease origin.

Rectal cancer deaths among millennials under 45 are rising 2–3 times faster than colon cancer. Doctors urge early symptom ...